209 related articles for article (PubMed ID: 32931811)
21. Evidence-Based Guidance for Self-Administration of Injectable Contraception.
Marx M
J Midwifery Womens Health; 2021 Jan; 66(1):108-112. PubMed ID: 33369137
[TBL] [Abstract][Full Text] [Related]
22. Expanding Access to Injectable Contraception: Results From Pilot Introduction of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) in 4 African Countries.
Stout A; Wood S; Barigye G; Kaboré A; Siddo D; Ndione I
Glob Health Sci Pract; 2018 Mar; 6(1):55-72. PubMed ID: 29602866
[TBL] [Abstract][Full Text] [Related]
23. Introduction of Community-Based Provision of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) in Benin: Programmatic Results.
Okegbe T; Affo J; Djihoun F; Zannou A; Hounyo O; Ahounou G; Bangbola KA; Harris N
Glob Health Sci Pract; 2019 Jun; 7(2):228-239. PubMed ID: 31171559
[TBL] [Abstract][Full Text] [Related]
24. A Pilot Study of Adolescent and Young Adult Experience with Subcutaneous Depot Medroxyprogesterone Acetate.
Wernick HJ; Wentzel E; Jackson K; Schmuhl K; Valenti O; Bonny AE; Berlan ED
J Pediatr Adolesc Gynecol; 2023 Dec; 36(6):549-552. PubMed ID: 37354986
[TBL] [Abstract][Full Text] [Related]
25. Provision of DMPA-SC for self-administration in different practice settings during the COVID-19 pandemic: Data from providers across the United States.
Comfort AB; Alvarez A; Goodman S; Upadhyay U; Mengesha B; Karlin J; Shokat M; Blum M; Harper CC
Contraception; 2024 Mar; 131():110360. PubMed ID: 38158075
[TBL] [Abstract][Full Text] [Related]
26. Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density.
Kaunitz AM; Darney PD; Ross D; Wolter KD; Speroff L
Contraception; 2009 Jul; 80(1):7-17. PubMed ID: 19501210
[TBL] [Abstract][Full Text] [Related]
27. Pilot study of home self-administration of subcutaneous depo-medroxyprogesterone acetate for contraception.
Cameron ST; Glasier A; Johnstone A
Contraception; 2012 May; 85(5):458-64. PubMed ID: 22079602
[TBL] [Abstract][Full Text] [Related]
28. The safety of subcutaneously administered depot medroxyprogesterone acetate (104mg/0.65mL): A systematic review.
Dragoman MV; Gaffield ME
Contraception; 2016 Sep; 94(3):202-15. PubMed ID: 26874275
[TBL] [Abstract][Full Text] [Related]
29. Introduction of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) Injectable Contraception at Facility and Community Levels: Pilot Results From 4 Districts of Uganda.
Odwe G; Gray K; Kyarimpa A; Obare F; Nagendi G
Glob Health Sci Pract; 2018 Dec; 6(4):711-722. PubMed ID: 30429201
[TBL] [Abstract][Full Text] [Related]
30. Factors associated with provision of depot medroxyprogesterone acetate to adolescents by US health care providers.
Ermias Y; Morgan IA; Curtis KM; Whiteman MK; Horton LG; Zapata LB
Contraception; 2019 May; 99(5):300-305. PubMed ID: 30763582
[TBL] [Abstract][Full Text] [Related]
31. Evaluating the feasibility and acceptability of self-injection of subcutaneous depot medroxyprogesterone acetate (DMPA) in Senegal: a prospective cohort study.
Cover J; Ba M; Lim J; Drake JK; Daff BM
Contraception; 2017 Sep; 96(3):203-210. PubMed ID: 28673645
[TBL] [Abstract][Full Text] [Related]
32. Society of Family Planning committee consensus on self-administration of subcutaneous depot medroxyprogesterone acetate (DMPA-SC).
Kohn JE; Berlan ED; Tang JH; Beasley A
Contraception; 2022 Aug; 112():11-13. PubMed ID: 35378085
[TBL] [Abstract][Full Text] [Related]
33. Predictors of DMPA-SC continuation among urban Nigerian women: the influence of counseling quality and side effects.
Liu J; Shen J; Diamond-Smith N
Contraception; 2018 Nov; 98(5):430-437. PubMed ID: 29733817
[TBL] [Abstract][Full Text] [Related]
34. Observational study of the acceptability of Sayana® Press among intramuscular DMPA users in Uganda and Senegal.
Burke HM; Mueller MP; Perry B; Packer C; Bufumbo L; Mbengue D; Mall I; Daff BM; Mbonye AK
Contraception; 2014 May; 89(5):361-7. PubMed ID: 24631328
[TBL] [Abstract][Full Text] [Related]
35. An observational study to test the acceptability and feasibility of using medical and nursing students to instruct clients in DMPA-SC self-injection at the community level in Kinshasa.
Bertrand JT; Bidashimwa D; Makani PB; Hernandez JH; Akilimali P; Binanga A
Contraception; 2018 Nov; 98(5):411-417. PubMed ID: 30120925
[TBL] [Abstract][Full Text] [Related]
36. Young Women's Experiences With Subcutaneous Depot Medroxyprogesterone Acetate: A Secondary Analysis of a One-Year Randomized Trial in Malawi.
Burke HM; Chen M; Packer C; Fuchs R; Ngwira B
J Adolesc Health; 2020 Nov; 67(5):700-707. PubMed ID: 32389457
[TBL] [Abstract][Full Text] [Related]
37. Patient experiences switching from in-clinic to self-administration of injectable contraception in two Western US states.
Newmark RL; Hodge CC; Shih G; Karlin J
Perspect Sex Reprod Health; 2024 Jul; ():. PubMed ID: 38965382
[TBL] [Abstract][Full Text] [Related]
38. Pharmacist-administered subcutaneous depot medroxyprogesterone acetate: a pilot randomized controlled trial.
Picardo C; Ferreri S
Contraception; 2010 Aug; 82(2):160-7. PubMed ID: 20654757
[TBL] [Abstract][Full Text] [Related]
39. Comparison of Female Genital Tract Cytokine and Microbiota Signatures Induced by Initiation of Intramuscular DMPA and NET-EN Hormonal Contraceptives - a Prospective Cohort Analysis.
Dabee S; Tanko RF; Brown BP; Bunjun R; Balle C; Feng C; Konstantinus IN; Jaumdally SZ; Onono M; Nair G; Palanee-Phillips T; Gill K; Baeten JM; Bekker LG; Passmore JS; Heffron R; Jaspan HB; Happel AU
Front Immunol; 2021; 12():760504. PubMed ID: 34956191
[TBL] [Abstract][Full Text] [Related]
40. Introducing the subcutaneous depot medroxyprogesterone acetate injectable contraceptive via social marketing: lessons learned from Nigeria's private sector.
Liu J; Schatzkin E; Omoluabi E; Fajemisin M; Onuoha C; Erinfolami T; Ayodeji K; Ogunmola S; Shen J; Diamond-Smith N; Sieverding M
Contraception; 2018 Nov; 98(5):438-448. PubMed ID: 30071196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
